SCHEMBL5937232

SCHEMBL5937232

Clc1ccc(Br)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31198814 1.00
SCHEMBL29367162 0.80
SCHEMBL610831 0.80
SCHEMBL29451087 0.80
SCHEMBL111337 0.80
Ammonia Solution, Strong SCHEMBL25301697 0.77
SCHEMBL7043561 0.71
SCHEMBL1456362 0.69 ALDH1A1 (0.46)
SCHEMBL29862129 0.67
SCHEMBL321951 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743445-A1 NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER Daewoong Pharmaceutical Co., Ltd. (KR) 2026-05-20 EP disclosed
US-20250275959-A1 COMPOUNDS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. 2025-09-04 US disclosed
WO-2025072330-A1 KIT INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-04-03 WO disclosed
WO-2025056068-A1 BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 上海济煜医药科技有限公司 2025-03-20 WO disclosed
EP-4499630-A1 BCL-XL INHIBITORS BeiGene, Ltd. (KY) 2025-02-05 EP disclosed
US-20250034128-A1 BCL-XL INHIBITORS BEIGENE, LTD. (KY) 2025-01-30 US disclosed
WO-2025014314-A1 NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2025-01-16 WO disclosed
CN-119306664-A Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same 株式会社大熊制药 2025-01-14 CN disclosed
WO-2024249950-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION, INC. (US) 2024-12-05 WO disclosed
CN-118994182-A Seleno-, thio-or oxo-narcotine derivatives, their synthesis and their use in tumour therapy 华东理工大学 2024-11-22 CN disclosed
WO-2016065582-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-05-06 WO disclosed
CN-105143209-A Biaryl amide compounds as kinase inhibitors NOVARTIS AG 2015-12-09 CN disclosed
WO-2015090600-A1 FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES AS CAV2.2 CALCIUM CHANNEL BLOCKERS Grünenthal GmbH (DE) 2015-06-25 WO disclosed
US-20140213570-A1 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS NOVARTIS AG (CH) 2014-07-31 US disclosed
US-8729263-B2 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions NOVARTIS AG (CH) 2014-05-20 US disclosed
US-20140051672-A1 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2014-02-20 US disclosed
US-20060052384-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia GLAXO GROUP LIMITED (GB) 2006-03-09 US disclosed
WO-2005092304-A2 ANTIFUNGAL AGENTS F2G LTD (GB) 2005-10-06 WO disclosed
EP-1539158-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2005-06-15 EP disclosed
WO-2004006922-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 WO disclosed